DK1411118T3 - Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof - Google Patents

Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof

Info

Publication number: DK1411118T3
Authority: DK; Denmark
Prior art keywords: antibody; glypican; cell proliferation; proliferation inhibitors; containing anti
Prior art date: 2001-06-22

Application number

DK02741243T

Other languages

English (en)

Inventor

Hiroyuki Aburatani

Tetsuo Nakamura

Masayuki Tsuchiya

Original Assignee

Chugai Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-22

Filing date

2002-06-21

Publication date

2008-11-17

2002-06-21 Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd

2008-11-17 Application granted granted Critical

2008-11-17 Publication of DK1411118T3 publication Critical patent/DK1411118T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Mycology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

DK02741243T 2001-06-22 2002-06-21 Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof DK1411118T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2001189443		2001-06-22
PCT/JP2002/006237 WO2003000883A1 (fr)	2001-06-22	2002-06-21	Inhibiteurs de proliferation cellulaire renfermant un anticorps anti-glypicane 3

Publications (1)

Publication Number	Publication Date
DK1411118T3 true DK1411118T3 (da)	2008-11-17

Family

ID=19028362

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK10003378.6T DK2208784T3 (da)	2001-06-22	2002-06-21	Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof
DK02741243T DK1411118T3 (da)	2001-06-22	2002-06-21	Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK10003378.6T DK2208784T3 (da)	2001-06-22	2002-06-21	Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof

Country Status (14)

Country	Link
US (3)	US20040236080A1 (da)
EP (3)	EP2208784B1 (da)
JP (7)	JP4281869B2 (da)
KR (3)	KR100953520B1 (da)
CN (2)	CN1314803C (da)
AT (2)	ATE407204T1 (da)
AU (2)	AU2002315857B2 (da)
CA (1)	CA2451493C (da)
CY (1)	CY1113854T1 (da)
DE (2)	DE60228721D1 (da)
DK (2)	DK2208784T3 (da)
ES (3)	ES2399028T3 (da)
PT (2)	PT1411118E (da)
WO (1)	WO2003000883A1 (da)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7361336B1 (en) *	1997-09-18	2008-04-22	Ivan Bergstein	Methods of cancer therapy targeted against a cancer stem line
ES2399028T3 (es) *	2001-06-22	2013-03-25	Chugai Seiyaku Kabushiki Kaisha	Inhibidores de la proliferación celular que contienen anticuerpo anti-glipicano 3
ES2324029T3 (es) *	2002-05-23	2009-07-29	Sunnybrook And Women's College Health Sciences Centre	Diagnostico de carcinoma hepatocelular.
AU2002338020A1 (en) *	2002-09-04	2004-03-29	Chugai Seiyaku Kabushiki Kaisha	Antibody against blood-solubilized n-terminal peptide in gpc3
WO2005023301A1 (ja) *	2003-09-04	2005-03-17	Chugai Seiyaku Kabushiki Kaisha	胆管癌治療剤および検出薬
ES2353967T3 (es) *	2004-07-09	2011-03-08	Chugai Seiyaku Kabushiki Kaisha	Anticuerpo anti-glipicano 3 .
US7871613B2 (en) *	2004-08-24	2011-01-18	Chugai Seiyaku Kabushiki Kaisha	Adjuvant therapy with the use of anti-glypican 3 antibody
WO2006046751A1 (ja) *	2004-10-26	2006-05-04	Chugai Seiyaku Kabushiki Kaisha	糖鎖改変抗グリピカン３抗体
CA2603408C (en)	2005-03-31	2018-08-21	Chugai Seiyaku Kabushiki Kaisha	Methods for producing polypeptides by regulating polypeptide association
BRPI0614259A2 (pt)	2005-08-03	2012-01-24	Matsushita Electric Industrial Co., Ltd	aparelho de estação de base, aparelho de terminal de comunicação, e, método de comunicação de múltiplas portadoras
US20070087005A1 (en)	2005-10-14	2007-04-19	Lazar Gregory A	Anti-glypican-3 antibody
US7723043B2 (en) *	2006-01-04	2010-05-25	Picobella, Lp	Methods for screening for prostate cancer
CN105177091A (zh)	2006-03-31	2015-12-23	中外制药株式会社	用于纯化双特异性抗体的抗体修饰方法
EP4001409A1 (en)	2006-03-31	2022-05-25	Chugai Seiyaku Kabushiki Kaisha	Methods for controlling blood pharmacokinetics of antibodies
KR101527342B1 (ko) *	2007-07-17	2015-06-09	메다렉스, 엘.엘.시.	글리피칸-3에 대한 단클론 항체
US9096651B2 (en)	2007-09-26	2015-08-04	Chugai Seiyaku Kabushiki Kaisha	Method of modifying isoelectric point of antibody via amino acid substitution in CDR
CA2978687C (en)	2007-09-26	2020-02-18	Chugai Seiyaku Kabushiki Kaisha	Modified antibody constant region
WO2009041062A1 (ja)	2007-09-28	2009-04-02	Chugai Seiyaku Kabushiki Kaisha	血漿中動態が改善されたグリピカン３抗体
MX337081B (es) *	2007-12-05	2016-02-10	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-nr10 y su uso.
CL2009000647A1 (es)	2008-04-04	2010-06-04	Chugai Pharmaceutical Co Ltd	Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
LT2708559T (lt)	2008-04-11	2018-06-11	Chugai Seiyaku Kabushiki Kaisha	Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
TWI440469B (zh)	2008-09-26	2014-06-11	Chugai Pharmaceutical Co Ltd	Improved antibody molecules
EP2409991B1 (en)	2009-03-19	2017-05-03	Chugai Seiyaku Kabushiki Kaisha	Antibody constant region variant
WO2010107109A1 (ja)	2009-03-19	2010-09-23	中外製薬株式会社	抗体定常領域改変体
US10150808B2 (en)	2009-09-24	2018-12-11	Chugai Seiyaku Kabushiki Kaisha	Modified antibody constant regions
WO2011108714A1 (ja)	2010-03-04	2011-09-09	中外製薬株式会社	抗体定常領域改変体
ES2660151T3 (es)	2010-11-17	2018-03-21	Chugai Seiyaku Kabushiki Kaisha	Molécula de unión a antígeno multiespecífica que tiene función alternativa a la función del factor VIII de coagulación sanguínea
AU2011337697B2 (en)	2010-11-30	2016-10-27	Chugai Seiyaku Kabushiki Kaisha	Cytotoxicity-inducing therapeutic agent
SG190727A1 (en)	2010-11-30	2013-07-31	Chugai Pharmaceutical Co Ltd	Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US20120190049A1 (en) *	2010-12-10	2012-07-26	University Of Washington Through Its Center For Commercialization	Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles
SG192945A1 (en)	2011-02-25	2013-09-30	Chugai Pharmaceutical Co Ltd	Fcgriib-specific fc antibody
EP3825325A3 (en)	2011-03-30	2021-10-13	Chugai Seiyaku Kabushiki Kaisha	Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
US20140335089A1 (en)	2011-09-30	2014-11-13	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule for promoting elimination of antigens
KR102239138B1 (ko)	2011-09-30	2021-04-12	추가이 세이야쿠 가부시키가이샤	표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
TW201817745A (zh)	2011-09-30	2018-05-16	日商中外製藥股份有限公司	具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP3939996A1 (en)	2011-09-30	2022-01-19	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
EP3617313A1 (en)	2011-10-05	2020-03-04	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain
ES2795419T3 (es)	2012-02-24	2020-11-23	Chugai Pharmaceutical Co Ltd	Molécula de unión al antígeno que promueve la desaparición del antígeno vía Fc RIIB
CA2874721A1 (en)	2012-05-30	2013-12-05	Tomoyuki Igawa	Target tissue-specific antigen-binding molecule
WO2013181543A1 (en) *	2012-06-01	2013-12-05	The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services	High-affinity monoclonal antibodies to glypican-3 and use thereof
TWI693073B (zh)	2012-12-21	2020-05-11	日商中外製藥股份有限公司	對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
EP4119947A1 (en)	2012-12-21	2023-01-18	Chugai Seiyaku Kabushiki Kaisha	Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
CA2925256C (en)	2013-09-27	2023-08-15	Chugai Seiyaku Kabushiki Kaisha	Method for producing polypeptide heteromultimer
DK3078744T3 (da)	2013-12-04	2020-09-28	Chugai Pharmaceutical Co Ltd	Antigen-bindende molekyler, antigen-bindingsaktiviteten af hvilke varierer i henhold til koncentrationen af forbindelser, og biblioteker af molekylerne
CN106459959A (zh)	2014-05-08	2017-02-22	中外制药株式会社	对gpc3靶向治疗剂疗法有效的患者施用的gpc3靶向治疗剂
US9926377B2 (en) *	2014-05-22	2018-03-27	Genentech, Inc.	Anti-GPC3 antibodies and immunoconjugates
MA40764A (fr)	2014-09-26	2017-08-01	Chugai Pharmaceutical Co Ltd	Agent thérapeutique induisant une cytotoxicité
CN104829704B (zh) *	2014-12-15	2016-08-17	河北省科学院生物研究所	一种磷脂酰肌醇蛋白聚糖gpc3蛋白片段及其应用和制备的杂交瘤细胞株
TWI656133B (zh)	2014-12-19	2019-04-11	日商中外製藥股份有限公司	抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
RU2746356C2 (ru)	2014-12-19	2021-04-12	Чугаи Сейяку Кабусики Кайся	Антитела к с5 и способы их применения
JP6735005B2 (ja) *	2015-01-16	2020-08-05	グリピーホールディングスピーティーワイリミテッド	グリピカンエピトープおよびその使用
CA2974547A1 (en)	2015-02-05	2016-08-11	Chugai Seiyaku Kabushiki Kaisha	Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses thereof
TWI759261B (zh)	2015-02-27	2022-04-01	日商中外製藥股份有限公司	Ｉｌ－６受體抗體用於製備醫藥組成物的用途
WO2016159213A1 (ja)	2015-04-01	2016-10-06	中外製薬株式会社	ポリペプチド異種多量体の製造方法
JP7096667B2 (ja)	2015-07-01	2022-07-06	中外製薬株式会社	Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤
AU2016304060B2 (en) *	2015-08-03	2022-09-29	Crage Medical Co., Limited	Antibody against glypican-3 and application thereof
KR101796688B1 (ko)	2015-10-29	2017-12-01	재단법인 목암생명과학연구소	신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
ES2982393T3 (es) *	2015-11-09	2024-10-15	Childrens Hospital Philadelphia	Glipicano 2 como marcador de cáncer y diana terapéutica
EP3394098A4 (en)	2015-12-25	2019-11-13	Chugai Seiyaku Kabushiki Kaisha	ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
SG11201803989WA (en)	2015-12-28	2018-06-28	Chugai Pharmaceutical Co Ltd	Method for promoting efficiency of purification of fc region-containing polypeptide
AU2017233658B2 (en)	2016-03-14	2023-09-21	Chugai Seiyaku Kabushiki Kaisha	Cell injury inducing therapeutic drug for use in cancer therapy
US11767362B1 (en) *	2016-03-15	2023-09-26	Chugai Seiyaku Kabushiki Kaisha	Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
JP7320943B2 (ja)	2016-04-28	2023-08-04	中外製薬株式会社	抗体含有製剤
TWI693940B (zh)	2016-08-05	2020-05-21	日商中外製藥股份有限公司	Ｉｌ-８相關疾病之治療用或預防用組成物
US11793180B2 (en)	2016-08-22	2023-10-24	Chugai Seiyaku Kabushiki Kaisha	Gene-modified mouse expressing human GPC3 polypeptide
TWI776827B (zh)	2016-11-28	2022-09-11	日商中外製藥股份有限公司	能夠調節配體結合活性的配體結合分子
JP7185884B2 (ja)	2017-05-02	2022-12-08	国立研究開発法人国立精神・神経医療研究センター	Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
JP7382922B2 (ja)	2017-09-20	2023-11-17	中外製薬株式会社	Ｐｄ－１系結合アンタゴニストおよびｇｐｃ３標的化剤を使用する併用療法のための投与レジメン
WO2019088143A1 (ja)	2017-11-01	2019-05-09	中外製薬株式会社	生物活性が低下した抗体バリアントおよびアイソフォーム
WO2019107384A1 (ja)	2017-11-28	2019-06-06	中外製薬株式会社	リガンド結合活性が調整可能なリガンド結合分子
AR114112A1 (es)	2018-02-15	2020-07-22	Seattle Genetics Inc	Anticuerpos de glipicano 3 y conjugados de los mismos
US20210253672A1 (en)	2018-05-30	2021-08-19	Chugai Seiyaku Kabushiki Kaisha	Ligand-binding molecule containing single domain antibody
SG11202011751WA (en)	2018-06-22	2021-01-28	Kite Pharma Inc	Chimeric transmembrane proteins and uses thereof
US20210388109A1 (en)	2018-10-01	2021-12-16	Adicet Bio, Inc.	Compositions and methods regarding engineered and non-engineered gamma delta t-cells for treatment of solid tumors
CA3117212A1 (en)	2018-10-23	2020-04-30	Dragonfly Therapeutics, Inc.	Heterodimeric fc-fused proteins
WO2020189748A1 (ja)	2019-03-19	2020-09-24	中外製薬株式会社	Ｍｔａ依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ
WO2020246563A1 (ja)	2019-06-05	2020-12-10	中外製薬株式会社	抗体切断部位結合分子
US20220315909A1 (en)	2019-06-05	2022-10-06	Chugai Seiyaku Kabushiki Kaisha	Protease substrate, and polypeptide including protease cleavage sequence
KR20250095757A (ko)	2019-06-21	2025-06-26	카이트 파마 인코포레이티드	TGF-β 수용체 및 이의 사용 방법
CN116096353A (zh)	2020-04-22	2023-05-09	蜻蜓疗法股份有限公司	异二聚体fc融合蛋白的配制品、剂量方案和制造工艺
CN116194124A (zh)	2020-07-31	2023-05-30	中外制药株式会社	包含表达嵌合受体的细胞的药物组合物
CN118994403B (zh) *	2021-10-15	2025-04-01	乐普创一生物科技（上海）有限公司	抗磷脂酰肌醇蛋白聚糖3抗体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04228089A (ja)	1990-05-15	1992-08-18	Kanegafuchi Chem Ind Co Ltd	高カルシウム血症治療・予防剤
US6214973B1 (en) *	1993-11-19	2001-04-10	Chugai Seiyaku Kabushiki Kaisha	Reshaped human antibody to human medulloblastoma cells
KR100654645B1 (ko)	1995-04-27	2007-04-04	아브게닉스, 인크.	면역화된 제노마우스 유래의 인간 항체
UA76934C2 (en) *	1996-10-04	2006-10-16	Chugai Pharmaceutical Co Ltd	Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
JP3587664B2 (ja)	1996-10-04	2004-11-10	中外製薬株式会社	再構成ヒト抗ｈｍ１．２４抗体
JP4228089B2 (ja)	1997-03-11	2009-02-25	株式会社ニコン	過電流検知機構およびそれを用いた電子閃光装置
US7361336B1 (en) *	1997-09-18	2008-04-22	Ivan Bergstein	Methods of cancer therapy targeted against a cancer stem line
ES2293691T3 (es)	1997-10-03	2008-03-16	Chugai Seiyaku Kabushiki Kaisha	Anticuerpo humano natural.
JP3445153B2 (ja)	1998-06-04	2003-09-08	富士通株式会社	電話番号一時的使用装置及び方法
TWI290832B (en) *	1999-08-23	2007-12-11	Chugai Pharmaceutical Co Ltd	Expression enhancer for HM1.24 antigen
ES2399028T3 (es)	2001-06-22	2013-03-25	Chugai Seiyaku Kabushiki Kaisha	Inhibidores de la proliferación celular que contienen anticuerpo anti-glipicano 3

2002
- 2002-06-21 ES ES10003378T patent/ES2399028T3/es not_active Expired - Lifetime
- 2002-06-21 CN CNB028125703A patent/CN1314803C/zh not_active Expired - Lifetime
- 2002-06-21 ES ES07002896T patent/ES2353335T3/es not_active Expired - Lifetime
- 2002-06-21 KR KR1020097019979A patent/KR100953520B1/ko not_active Expired - Lifetime
- 2002-06-21 PT PT02741243T patent/PT1411118E/pt unknown
- 2002-06-21 DK DK10003378.6T patent/DK2208784T3/da active
- 2002-06-21 KR KR1020037016776A patent/KR100877176B1/ko not_active Expired - Lifetime
- 2002-06-21 AU AU2002315857A patent/AU2002315857B2/en not_active Expired
- 2002-06-21 US US10/481,524 patent/US20040236080A1/en not_active Abandoned
- 2002-06-21 EP EP10003378A patent/EP2208784B1/en not_active Expired - Lifetime
- 2002-06-21 PT PT100033786T patent/PT2208784E/pt unknown
- 2002-06-21 CA CA2451493A patent/CA2451493C/en not_active Expired - Lifetime
- 2002-06-21 KR KR1020087019090A patent/KR20080077295A/ko not_active Ceased
- 2002-06-21 WO PCT/JP2002/006237 patent/WO2003000883A1/ja not_active Ceased
- 2002-06-21 AT AT02741243T patent/ATE407204T1/de active
- 2002-06-21 DE DE60228721T patent/DE60228721D1/de not_active Expired - Lifetime
- 2002-06-21 CN CN2007100960379A patent/CN101240022B/zh not_active Expired - Lifetime
- 2002-06-21 EP EP07002896A patent/EP1780273B1/en not_active Expired - Lifetime
- 2002-06-21 AT AT07002896T patent/ATE483801T1/de not_active IP Right Cessation
- 2002-06-21 EP EP02741243A patent/EP1411118B1/en not_active Expired - Lifetime
- 2002-06-21 DE DE60237929T patent/DE60237929D1/de not_active Expired - Lifetime
- 2002-06-21 JP JP2003507268A patent/JP4281869B2/ja not_active Expired - Lifetime
- 2002-06-21 ES ES02741243T patent/ES2312586T3/es not_active Expired - Lifetime
- 2002-06-21 DK DK02741243T patent/DK1411118T3/da active
2005
- 2005-04-28 JP JP2005133154A patent/JP2005225892A/ja not_active Withdrawn
2006
- 2006-11-06 JP JP2006300276A patent/JP2007051159A/ja not_active Withdrawn
2007
- 2007-02-05 US US11/702,780 patent/US7744880B2/en not_active Expired - Lifetime
- 2007-03-22 AU AU2007201255A patent/AU2007201255B2/en not_active Expired
- 2007-06-25 JP JP2007165739A patent/JP2007238632A/ja active Pending
2008
- 2008-02-08 JP JP2008028527A patent/JP2008120828A/ja active Pending
- 2008-09-05 JP JP2008228128A patent/JP4347402B2/ja not_active Expired - Lifetime
2009
- 2009-04-24 JP JP2009105835A patent/JP5596935B2/ja not_active Expired - Lifetime
2010
- 2010-04-26 US US12/799,491 patent/US8263077B2/en not_active Expired - Fee Related
2013
- 2013-03-29 CY CY20131100264T patent/CY1113854T1/el unknown

Also Published As

Publication number	Publication date
CN101240022A (zh)	2008-08-13
EP1411118A1 (en)	2004-04-21
ES2353335T3 (es)	2011-03-01
EP2208784B1 (en)	2013-01-02
CN101240022B (zh)	2012-07-18
JP2007051159A (ja)	2007-03-01
KR100877176B1 (ko)	2009-01-07
WO2003000883A1 (fr)	2003-01-03
JP2009161565A (ja)	2009-07-23
DE60228721D1 (en)	2008-10-16
JP2008120828A (ja)	2008-05-29
ES2399028T3 (es)	2013-03-25
CN1314803C (zh)	2007-05-09
US20070172488A1 (en)	2007-07-26
CN1688692A (zh)	2005-10-26
EP1780273A1 (en)	2007-05-02
KR20090107091A (ko)	2009-10-12
US8263077B2 (en)	2012-09-11
JPWO2003000883A1 (ja)	2004-10-07
CA2451493C (en)	2016-08-23
DE60237929D1 (de)	2010-11-18
CY1113854T1 (el)	2016-07-27
HK1079547A1 (en)	2006-04-07
JP2009024020A (ja)	2009-02-05
JP5596935B2 (ja)	2014-09-24
EP1411118A4 (en)	2005-01-26
JP4281869B2 (ja)	2009-06-17
EP1411118B1 (en)	2008-09-03
ATE407204T1 (de)	2008-09-15
AU2007201255A1 (en)	2007-04-19
KR100953520B1 (ko)	2010-04-21
JP2007238632A (ja)	2007-09-20
US7744880B2 (en)	2010-06-29
EP1780273B1 (en)	2010-10-06
US20040236080A1 (en)	2004-11-25
KR20040030699A (ko)	2004-04-09
JP2005225892A (ja)	2005-08-25
AU2007201255B2 (en)	2010-03-11
US20110002922A1 (en)	2011-01-06
DK2208784T3 (da)	2013-03-18
EP2208784A1 (en)	2010-07-21
HK1120522A1 (en)	2009-04-03
PT1411118E (pt)	2008-12-09
CA2451493A1 (en)	2003-01-03
AU2002315857B2 (en)	2007-07-26
ES2312586T3 (es)	2009-03-01
PT2208784E (pt)	2013-04-03
ATE483801T1 (de)	2010-10-15
JP4347402B2 (ja)	2009-10-21
KR20080077295A (ko)	2008-08-21

Publication	Publication Date	Title
DK1411118T3 (da)	2008-11-17	Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof
BRPI0317696B8 (pt)	2021-05-25	composição para branqueamento
ATE363280T1 (de)	2007-06-15	Verwendung von pioglitazone zur verbesserung der ketose und der azidose
CY1106766T1 (el)	2012-05-23	Παραγωγα πυριδινης ως αναστολεις raf κινασης
SE0102327D0 (sv)	2001-06-28	A novel engineered superantigen for human therapy
TR200002480T2 (tr)	2000-12-21	İzaşemi tedavisi için guanidin türevleri
TW200505890A (en)	2005-02-16	Breast cancer-resistant protein inhibitor
TR200200883T2 (tr)	2002-09-23	2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları
BRPI0410467A (pt)	2006-05-30	composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
IL156774A0 (en)	2004-02-08	Inhibitors of cruzipain and other cysteine proteases
BR0014758A (pt)	2002-07-02	Sistemas e métodos para expressão de proteìna com alto rendimento
HN2002000366A (es)	2003-04-21	Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma
DE50310323D1 (de)	2008-09-25	Wässrige polyurethanzubereitungen
DE50009838D1 (de)	2005-04-28	Humanes antibiotisches protein
DE60125232D1 (de)	2007-01-25	Kleines säurelösliches sporenprotein und seine verwendungen
DK1368022T3 (da)	2007-10-01	Anvendelse af en flaske indeholdende en oxaliplatinoplösning
IT1317049B1 (it)	2003-05-26	Composti utili per la preparazione di medicamenti ad attivita'inibitrice della fosfodiesterasi iv.
ATE269313T1 (de)	2004-07-15	Tryptase-inhibitoren
ATE392644T1 (de)	2008-05-15	Alpha-(1' -hydroxyalkyl)acrylate enthaltende beschichtungsmassen
PT1244614E (pt)	2004-10-29	Inibidores de triptase
DE502004012439D1 (de)	2011-06-09	Medikament und verwendung zur tumortherapie
DK1438411T3 (da)	2006-11-20	Anvendelse af aminogylcosid-resistensgen
DK0733370T3 (da)	2003-04-07	Anvendelse af en genpromotorsekvens til behandling af rheumatiske sygdomme
PT1380208E (pt)	2005-09-30	Agente desinfectante com actividade antiparasitica
ATE382363T1 (de)	2008-01-15	Pharmazeutische zusammensetzung enthaltend bulbophyllum